Table 1 Patient characteristics.
Patient characteristics | All eligible rrDLBCL | Patient characteristics | All eligible rrDLBCL |
|---|---|---|---|
(N = 228) | (N = 228) | ||
Age at diagnosis | Â | Dark-zone signature, n (%) | Â |
 Mean (SD) | 62.4 (13) |  ABC | 68 (46.6%) |
 Median | 64.0 |  GCB | 39 (26.7%) |
 IQR | 55.0, 72.0 |  DZsig+ | 24 (16.4%) |
 Range | 24.0, 91.0 |  Unclassified | 15 (10.3%) |
Age Group, n (%) | Â | EFS24, n (%) | Â |
 ≤60 | 91 (41.0%) |  Achieved | 36 (23.8%) |
 >60 | 131 (59.0%) |  Failed | 115 (76.2%) |
Sex, n (%) | Â | Last follow-up, n (%) | Â |
 Male | 142 (64.0%) |  Alive | 52 (28.0%) |
 Female | 80 (36.0%) |  Dead | 134 (72.0%) |
PS Group, n (%) | Â | Primary COD, n (%) | Â |
 <2 | 120 (85.7%) |  Disease | 88 (88.0%) |
 ≥2 | 20 (14.3%) |  Therapy | 5 (5.0%) |
Ann Arbor Stage, n (%) |  |  Other | 7 (7.0%) |
 I–II | 37 (24.2%) | Dx to relapse sample (Mo) |  |
 III–IV | 116 (75.8%) |  Mean (SD) | 24.9 (28) |
aaIPI, n (%) |  |  Median | 13.8 |
 0 | 33 (15.1%) |  IQR | 7.9, 29.0 |
 1 | 87 (39.7%) |  Range | 1.64, 149.8 |
 2 | 82 (37.4%) | Relapse to last follow-up |  |
 3 | 17 (7.8%) |  Mean (SD) | 39.9 (53) |
Extranodal sites, n (%) |  |  Median | 10.2 |
 0–1 extranodal sites | 122 (77.2%) |  IQR | 3.45, 65.0 |
 2 or more extranodal sites | 36 (22.8%) |  Range | 0.03, 210.1 |
Bulky disease, n (%) | Â | Sample Type, n (%) | Â |
 Yes | 13 (8.4%) |  R1 | 96 (60.8%) |
 No | 142 (91.6%) |  R2 | 36 (22.8%) |
Bone marrow involv., n (%) |  |  R3 | 17 (10.8% |
 Yes | 33 (23.2%) |  R4 | 4 (2.5%) |
 None | 109 (76.8%) |  R5 | 2 (1.3%) |
B symptoms, n (%) |  |  R6 | 1 (0.6%) |
 Yes | 44 (30.1%) |  R7 | 1 (0.6%) |
 No | 102 (69.9%) |  R10 | 1 (0.6%) |
LDH group, n (%) | |||
 Elevated | 110 (67.5%) |  |  |
 Not elevated | 53 (32.5%) |  |  |
